Elevating precision medicine to the forefront of every cancer treatment journey
Our vision is a future in which each tumor’s unique genomic test result can be matched with a purpose-built precision medicine.
Together with our drug and diagnostic developer peers, we work to enable a personalized treatment plan for each individual patient with cancer.
Our Focus
Genomic testing illuminates the path
Your tumor has a genomic fingerprint that may help your physician map the best path to overcoming it.
We advocate for every patient to get their tumor genomically tested. Only through testing can we give patients their best chance at improved outcomes.
Learn More About Genomic Testing Patient-Doctor Discussion Guide
Blazing the trail to make genomic test results actionable
We develop drugs to inhibit the specific alterations that have been identified as drivers of cancer ⏤ no matter how rare.
Our lead drug candidate, seribantumab, inhibits tumor growth driven by NRG1 gene fusions. Seribantumab is being studied in CRESTONE, a Phase 2 trial for patients with solid tumors of any origin that test positive for an NRG1 fusion.
Learn More About CRESTONE
(re)Vision
SHAWN LELAND | APRIL 2021
There is an innate paradox in how big, yet small, one can feel after summiting a challenging peak. The accomplishment of making it to the top is quickly surpassed by a humbling recognition of all that can now be seen, and the vast opportunities ahead. At Elevation Oncology, we embrace this dichotomy every day. We are fully focused on reaching the top of our first summit, NRG1 fusions, through execution of our Phase 2 CRESTONE study with efficiency and excellence. At the same time, we actively drive towards the much bigger picture – our founding vision of elevating precision medicine to the forefront of every cancer treatment journey. We hope that by sharing more of our vision, you may also be inspired towards action.
Read the full letter